Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 9/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | ADCYAP1R1 | P41586 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3471407 | 0.73 | KMT2A (0.48) | KMT2AKDM4EMAPT | |
| SCHEMBL3169119 | 0.72 | KMT2A (0.57) | KMT2AKDM4E | |
| SCHEMBL30052151 | 0.71 | KMT2A (0.56) | KMT2AKDM4EMEN1MAPT | |
| SCHEMBL13065371 | 0.71 | KMT2A (0.56) | KMT2AKDM4EMAPT | |
| SCHEMBL3174313 | 0.71 | KMT2A (0.56) | KMT2AKDM4EMEN1MAPT | |
| SCHEMBL12875609 | 0.71 | KMT2A (0.56) | KMT2AKDM4EMEN1 | |
| SCHEMBL20037232 | 0.71 | KMT2A (0.56) | KMT2AKDM4E | |
| SCHEMBL2777064 | 0.71 | STAT3 (0.67) | KMT2AKDM4EMEN1PTGDR2MAPT | |
| SCHEMBL15157114 | 0.68 | HTR2C (0.57) | KMT2AKDM4E | |
| SCHEMBL8685214 | 0.68 | KMT2A (0.51) | KMT2AGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113796-A1 | INDOLE DERIVATIVES AS S1P1 RECEPTOR | GLAXO GROUP LIMITED | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113796-A1 | INDOLE DERIVATIVES AS S1P1 RECEPTOR | S1PR1, S1PR3, S1PR2 | GCGR 130/4885KMT2A 2344/4885ADCYAP1R1 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.